UnitedHealth reported full-year 2025 revenue of $447.6 billion, marking a 12% increase from the prior year, yet fell short of internal projections for the quarter. Adjusted earnings from operations declined by 36.9%, dropping to $21.7 billion from $34.4 billion in 2024. Management attributed part of the decline to a $799 million net impact from a significant cyberattack and a $2.521 billion hit related to restructuring charges. For 2026, the company guided to revenue in excess of $439 billion, implying flat or modest growth year-over-year if targets are met, and signaling a cautious outlook for the upcoming period.

Shares have retraced sharply, falling approximately 47% over the trailing 12 months, which has compressed key valuation multiples. The company’s trailing 12-month price-to-earnings ratio stands at 17.51x, about 17.34% below its five-year average, while the trailing price-to-sales ratio of 0.58x is 55.22% below its historical norm. The board has maintained a forward annual dividend yield near 3.1%, underscoring its commitment to returning capital even as the stock weathers headwinds. These metrics suggest that much of the current pessimism may already be factored into the share price, presenting a possible entry point for long-term investors.

Regulatory developments in Medicare Advantage payments have driven recent volatility: the proposal of a 0.09% average increase for 2027 plan rates fell well short of market expectations for a 4%–6% bump, prompting a notable sell-off. A sizable portion of UnitedHealth’s revenue is tied to these plan reimbursements, so sentiment has shifted quickly on the announcement. However, the modest rate adjustment remains in draft form and could be revised in the coming weeks. Analysts note that any improvement or clarification on the final rate could spark a material rebound in shares, especially given the long‐term demographic tailwinds from an aging population that underlie demand for private Medicare Advantage offerings.